Status:

UNKNOWN

A First in Human Evaluation of a Novel Approach to Painless Cardioversion (NAPC) in Patients With Atrial Fibrillation

Lead Sponsor:

MediCool Technologies

Conditions:

Atrial Fibrillation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

An assessment of the use of cold therapy to terminate atrial fibrillation.

Eligibility Criteria

Inclusion

  • Subject must be ≥ 18 years or older
  • Male of female
  • Subject has documented paroxysmal, or persistent atrial fibrillation (AF) with a history of less than one-year duration
  • Must be in AF at time of surgery, or inducible using manual or electrical stimulation
  • Subject is willing and able to provide written informed consent
  • Subject has a life expectancy of at least 1 year

Exclusion

    Key Trial Info

    Start Date :

    April 1 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 1 2023

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT05324540

    Start Date

    April 1 2022

    End Date

    March 1 2023

    Last Update

    April 12 2022

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    A First in Human Evaluation of a Novel Approach to Painless Cardioversion (NAPC) in Patients With Atrial Fibrillation | DecenTrialz